On November 16, the "2019 Western China (Meishan) International Medical Exchange and Investment Summit & International Thyroid & Parathyroid Medicine Conference" co-sponsored by the People's Government of Dongpo District, Meishan, Sichuan International Medical Exchange & Promotion Association (SCIMEA), the Management Committee of New District of Meishan Economic Development Zone, West China Hospital, Sichuan University, Sichuan Cancer Society, and Sichuan Association of Rehabilitation Medicine was held in Meishan, Sichuan Province. Leaders such as Lu Mingchun, secretary of the Party Working Committee of the New District of Meishan Economic Development Zone, Liu Xianrang, director of the Academic Society of Sichuan Association for Science and Technology, will be invited to the conference. Many experts, such as Zhu Jingqiang, professor of thyroid surgery, West China Hospital, Zhang Mengfan, secretary-general of Sichuan International Medical Exchange & Promotion Association, Professor Liao Quan from the Department of Thyroid Surgery of Peking Union Medical College Hospital, and well-known multidisciplinary experts of parathyroid diseases in China and Sichuan Province gave wonderful academic lectures.
Professor Zhu Jingqiang, chairman of the conference, secretary of the Party Working Committee of the New District of Meishan Economic Development Zone, Lu Mingchun, Liu Xianrang, director of the Academic Society of Sichuan Association for Science and Technology, and Zhang Mengfan, secretary-general of Sichuan International Medical Exchange & Promotion Association, successively delivered their speeches.
Professor Zhu Jingqiang extended his thanks to the leaders and experts who have always supported the development of thyroid medicine. As the new chairman of Thyroid and Parathyroid Disease Special Committee of SCIMEA, he extended his high expectation for the Special Committee. He hopes it can contribute to the thyroid diagnosis and treatment in Sichuan with exploration of new methods and experiments. He also mentioned the active role of Western Medicine Valley in promoting the transformation of medical research achievements.
Lu Mingchun, secretary of the Party Working Committee of the New District of Meishan Economic Development Zone, mentioned that Dongpo District is the central urban area of Meishan. It was listed as the economic development model county, and it successfully became one of the top 100 national investment potential strength county and top 100 new urbanization quality district, a hot spot of investment with great potential and great business opportunities in western China. Regarding projects, the "Western Medicine Valley" has a total planned area of 36 square kilometers and is mainly for the development of the pharmaceutical industry. It is a provincial-level high-tech industrial park, top ten key medical parks for development in Sichuan, and the first batch of pilot drug demonstration zone with license system in Sichuan. A number of leading projects with core technology and independent innovation capabilities have settled in the park, such as West China Pharmaceutical Industrial Park, Staidson, Yifan Pharmaceutical, and Gowell Pharma. It has gathered 56 biomedicine and related companies. Its output value and tax revenue have been doubled for three consecutive years, and it expects another double this year. It has become a hot spot for the pharmaceutical industry in Chengdu Plain with great vitality, potential and business opportunities. We sincerely invite people to Meishan, develop in Dongpo District, and play an important part in the Medicine Valley.
Liu Xianrang, , director of the Academic Society of Sichuan Association for Science and Technology, said in his speech that the "2019 Western Medicine Valley Thyroid and Parathyroid Summit Forum" enjoys a high reputation in the pharmaceutical industry, and it provides a platform of communication and exchange for medical practitioners in the medical industry. On this platform, we will continue to improve the level of science & technology and industrialization in thyroid R&D in China through interactions with outstanding domestic multidisciplinary professors and young medical experts. The Science and Technology Department of Sichuan attaches great importance to the forum, and will conscientiously perform its duties in accordance with national laws, regulations and policies, with a goal to provide more convenient and effective services for the people.
Zhang Mengfan, secretary-general of Sichuan International Medical Exchange & Promotion Association, said that as one of the conference sponsors, SCIMEA has been devoted to co-innovation. It relies on a comprehensive platform, serves its members, stresses enterprise management, features projects difference, takes industrial development as its goal, fully understands the needs of its members, and meets their needs.
At present, SCIMEA has established nearly 20 special committees. In order to fit the theme of this conference and make full use of the advantages of SCIMEA, the establishment conference of the Special Medical Committee of Thyroid and Parathyroid Diseases of SCIMEA was held in Meishan yesterday. The special committee will integrate platform resources, build an academic exchange platform of diversity, carry out in-depth grassroots training, and jointly promote the development of thyroid disease treatment in the province.
Li Yujing, director of the Investment Promotion Bureau of Meishan Economic Development Zone, introduced products in Western Medicine Valley, introduced the unique advantages of Western Medicine Valley regarding park establishment, location, efficient government services, targeted industrial support, low operating costs, and beautiful ecological environment.
Professor Zhu Jingqiang from the Department of Thyroid Surgery of West China Hospital shared Interpretation of Expert Consensus for the Protection of Parathyroid Gland Function During Perioperative Thyroid Surgery-Nine Notices at Three Critical Moments, and gave a detailed explanation on parathyroid function protection guide of thyroid perioperative at three critical moments, i.e. the moment before, during and after surgery.
Professor Liao Quan of the Department of Thyroid Surgery, Peking Union Medical College Hospital elaborated on the Current Status of Diagnosis and Treatment of Hyperparathyroidism, where he used a large number of survey data to analyze the status of primary parathyroidism and secondary hypothyroidism regarding general symptoms, first symptoms, surgical status, postoperative follow-up, etc., as well as the progress and surgical positioning of the United States, France, Italy and other countries in the treatment of hyperparathyroidism.
Professor Dai Wenjie of the First Affiliated Hospital of Harbin Medical University mentioned in Selection and Evaluation of Renal Parathyroidism Surgery that the clinical incidence of chronic kidney disease (CKD) is as high as 10.8%, and research shows that 5-25% of CKD patients develop into severe SHPT, while 75% of CKD patients have persistent SHPT, which causes thyroid cells to form proliferative lesions or tumors. About 20% of patients with CKD hemodialysis for 3-10 years need surgical intervention for SHPT, and up to 40% of patients with 20 years of hemodialysis need surgical intervention for SHPT.
Based on research data from the UK, Denmark, Norway, Boston and other countries, Su Yanjun, professor of thyroid from Surgery Clinical Research Center for Thyroid Surgery and the First Affiliated Hospital of Kunming Medical University, elaborated on A Brief on Risks of Postoperative Hypoparathyroidism regarding risks and harms of hypoparathyroid patients in life, work, death, heart disease, kidney disease, fractures, etc.,.
Yu Zhengyang, Professor from the Department of Thyroid and Breast Surgery, The First Affiliated Hospital of University of South China, presented Intraoperative Identification and Protection of Parathyroidism: Preliminary Application of Near-Infrared Autofluorescence Imaging, where he said that the identification and protection of parathyroidism during surgery is still a clinical obstacle, while the development of Micro eye is of great significance to the clinical practice, and the era of fluorescent navigation surgery has come.
In order to better establish a platform for communication, learning and discussion for medical workers and guests, popularize the treatment and prevention of thyroid disease, and promote the progress of the thyroid related area in China, a thyroid forum, a CKD-MBD nutrition / calcium and phosphorus metabolism / calcification defense workshop, a training on new techniques of thyroid thermal ablation were held in the afternoon, with a goal to jointly promote the diagnosis and treatment strength with multi-disciplinary medical and nursing integration, and help Meishan, a millennial medical city, step onto a new stage professionalism in thyroid surgery.
